Rapamycin (Sirolimus)

For research use only.

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

1109 publications

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Rapamycin (Sirolimus) has been cited by 1109 publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MnvGR5l1d3SxeHnjJGF{e2G7 NHfCeowyOCCwTR?= MkLuO|IhcA>? M2nkSGROW09? NXj6c3FRWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MoXwNlQ6ODB6N{O=
HT-29 MXTDfZRwfG:6aXOgRZN{[Xl? MUKxNEBvVQ>? NVzVSY9{PzJiaB?= NGHXT3VFVVOR NVS3eG4yWG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 MlrYNlQ6ODB6N{O=
HT-29 M3vGUmN6fG:2b4jpZ{BCe3OjeR?= MnfhNVAhdk1? NIDKcHY4OiCq MkTwSG1UVw>? M3HxRnBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 Mn64NlQ6ODB6N{O=
PC3 MUXLbY5ie2ViQYPzZZk> MVyxNFAhdk1? M4HOfFEhcA>? NW\BT5BJTE2VTx?= NXz1XJB5WG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> Ml\GNlE6Pzh4OEO=
PC3 Mnv6T4lv[XOnIFHzd4F6 MmjCNVAxKG6P NF3MPJgyKGh? NHvHO2FFVVOR MoTtSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NX7zPFJDOjF7N{i2PFM>
PC3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTHWWoyNjVizszN MYmxJIg> MlHISG1UVw>? NVHUPY5WUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N Mmn1NlE6Pzh4OEO=
HEK293 MorFSpVv[3Srb36gRZN{[Xl? MkTyNVAxKG6P MWO4JIg> MmHXSG1UVw>? MXLJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? MofxNlE2Ozl|MEG=
BT-20 NVnleFRzU2mwYYPlJGF{e2G7 NFXIUGgzOCEQvF2= NUjm[IVVTE2VTx?= NW\tT|hYTG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= NVv6eGpSOjF|NUO1OVE>
U937 NEXNcGdCdnSrYnHjeIVzcWGuIFHzd4F6 NF20WYQ2OCEQvF2= M4iwW|Q5KGh? MlnRSG1UVw>? NWe5T5RvUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz MVqyNVE1OjFyNh?=
U937 NH33dpNCdnSrYnHjeIVzcWGuIFHzd4F6 NVTUfXNjPTBizszN MXS0PEBp MWjEUXNQ M1jt[WRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN? NVHo[lNrOjFzNEKxNFY>
U937 M{jpVmFvfGmkYXP0[ZJq[WxiQYPzZZk> M4Dtd|UxKM7:TR?= MWi0PEBp MnfmSG1UVw>? MW\Ec4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> NXXBdW96OjFzNEKxNFY>
MCF-7 NY\UNFhxSXW2b4DoZYd6KEG|c3H5 NGHFSoo{OCCwTR?= Mni0OEBp MlPUSG1UVw>? NHnyO21KdmS3Y3XzJIF2fG:yaHHnfS=> MXiyNFAzQDF|NB?=
U87MG NFrFTm9McW6jc3WgRZN{[Xl? NVrRZpNXOSEQvF2= M335N|YhcA>? MUTEUXNQ MXjQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? NWfjcYdEOTl6NEi0NFQ>
U87MG MXHLbY5ie2ViQYPzZZk> MnTnNUDPxE1? NEn5VGQ3KGh? NXr5TY9RTE2VTx?= MVLQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NI\uT4gyQTh2OESwOC=>
U87MG NHyzOW9McW6jc3WgRZN{[Xl? MX6xJO69VQ>? MmTuOkBp NXjmN4s6TE2VTx?= MmPFSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NIfzXo8yQTh2OESwOC=>
U87MG NHX1XXNMcW6jc3WgRZN{[Xl? MX[xJO69VQ>? MlPROkBp MWfEUXNQ NWjPOI9[TG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w Mkf3NVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb NWraOFF6SXW2b4DoZYd6KEG|c3H5 NGrke4kxNjJizszN M2HCPFI1KGh? Mo\jSG1UVw>? MnjoTY5lfWOnczDheZRweGijZ4m= NYTlcI96OTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 MXjBeZRweGijZ4mgRZN{[Xl? NFPsbpUxNjJizszN NHqw[FgzPCCq MWrEUXNQ M3Lp[Wlv\HWlZYOgZZV1d3CqYXf5 NHf1S|gyQDN7MUm0PS=>
H4 NYnyT|R{TnWwY4Tpc44hSXO|YYm= NH30T3UxNjJizszN MUeyOEBp MkHaSG1UVw>? M{TBNGlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> NXH6Z5F3OThyMkS1PFQ>
HeLa NGfLO2xHfW6ldHnvckBCe3OjeR?= MXixNFAhdk1? MXKzOkBp NGDuWYlFVVOR MX\JcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u MnnkNVc2PjN|OEW=
HeLa MXrGeY5kfGmxbjDBd5NigQ>? M4[4ZlExOCCwTR?= NXrLPGNZOzZiaB?= MXXEUXNQ MkW4TY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NYn6OY1mOTd3NkOzPFU>
HeLa M3O4OGZ2dmO2aX;uJGF{e2G7 NX7yWVF{OTByIH7N MkPUN|YhcA>? NWXvdYttTE2VTx?= MVTJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= MoqyNVc2PjN|OEW=
SYF MVLGeY5kfGmxbjDBd5NigQ>? MXSxNFAhdk1? NEXzS4czPCCq MnXISG1UVw>? NEK1[npKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NEO3WJgyPzV4M{O4OS=>
SYF M3S0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxNFAhdk1? MYSyOEBp NXjmdJgyTE2VTx?= NYrlU3RFUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> MlfrNVc2PjN|OEW=
HEK293T M4jmR2FvfGm4aYLhcEBCe3OjeR?= MnjrNUBvVQ>? M1;MV|Qh\A>? M4T0bWROW09? NELLU21KdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> M1z1dlE4PDh3NUCx
HEK293T NWPWd2w1SW62aY\pdoFtKEG|c3H5 NULnfpZ1OSCwTR?= MX60JIQ> M3rKTWROW09? NHrhVIhKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> M2js[lE4PDh3NUCx
PBMC MXrGeY5kfGmxbjDBd5NigQ>? NY\WT5RYOSCwTR?= NUfDd4NCOTRiZB?= MmHWSG1UVw>? NEjmNJRT\WS3Y3XzJGNEWjViZHXud4l1gQ>? MVKxO|Q5PTVyMR?=
PBMC MlPPSpVv[3Srb36gRZN{[Xl? M1LLZ|Ehdk1? MXSxOEBl NV\SOIR3TE2VTx?= M3LGb2Rw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6 NHizTmEyPzR6NUWwNS=>
HEK293 cells M{L6NGtqdmG|ZTDBd5NigQ>? NYPicFcxPTBibl2= NVXJVJJxPDVibXnu M{XSNWROW09? NIPUXnBKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P M4\ae|E4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M3fOWWZ2dmO2aX;uJGF{e2G7 NWTlO2RiOTByIH7N NF31[YU1KGh? NHLIe4ZFVVOR NH75fndKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? MWSxO|EzQDJ4Mh?=
Human mixed lymphocyte NGjOVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPkOUBvVQ>? MkHFSG1UVw>? M3XZbmlEPTB;MT62JI5ONg>? MkWwNVYyQDV6NkW=
Lewis rat lymph node cells MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrPUnptPSEQvF2= NVzacWZ6TE2VTx?= MV;JR|UxRTJwNjFOwG0> NW[xe3FNOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice M3jtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGxNEBvVQ>? M{fPflczKGh? NX3LS5NzTE2VTx?= NVuzem43UW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> NIfxeXUyODB{MUm0PC=>
MRK-nu-1 NXf3N4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H5eWlEPTB;MD64OFUheE1? MUjTRW5ITVJ?
OCUB-M MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OwTGlEPTB;NT6yOEBxVQ>? Mn:zV2FPT0WU
SF539 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXPTWM2OD1zMT62JJBO NXHEeZZyW0GQR1XS
ES4 NIrjcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:0N|NlUUN3ME2yNU42KHCP NFPHW2pUSU6JRWK=
RL95-2 M2TGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jNWGlEPTB;MUC3JJBO NFr6V5BUSU6JRWK=
LC-2-ad NH\4WIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDmTWM2OD12MkOgdG0> NEDBRXdUSU6JRWK=
Daudi MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW0NHdMUUN3ME20N|QheE1? MXjTRW5ITVJ?
NTERA-S-cl-D1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLKR3JKSzVyPUS0N{BxVQ>? MWHTRW5ITVJ?
OS-RC-2 NXvoNVdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHZTWM2OD14NUKgdG0> MYXTRW5ITVJ?
VA-ES-BJ MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn5[GhKSzVyPUeyN{BxVQ>? MVXTRW5ITVJ?
GR-ST M{TEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHoRlJKSzVyPUi0OkBxVQ>? NYi0bpY4W0GQR1XS
SW872 M3zBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTh2NjDwUS=> MXrTRW5ITVJ?
NOS-1 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTydXh{UUN3ME24O|EheE1? MVHTRW5ITVJ?
MC116 M3XPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOwN3pKSzVyPUm4OUBxVQ>? NHraNnhUSU6JRWK=
NCI-H1355 M{XVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfNXYVwUUN3ME2xMlAyKG6P MUfTRW5ITVJ?
RPMI-8226 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwMUmgcm0> NXLkW5FCW0GQR1XS
TE-15 NVzZSHR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfxb4ZIUUN3ME2xMlM3KG6P NG\hV4JUSU6JRWK=
Ramos-2G6-4C10 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnuOlhuUUN3ME2xMlQ3KG6P MYnTRW5ITVJ?
KU812 NUjHSWk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jiOGlEPTB;Mj6wNUBvVQ>? NHnMXGVUSU6JRWK=
EW-1 NXnVOGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWwTWM2OD1{LkG3JI5O NVXmNFRrW0GQR1XS
KS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vsRmlEPTB;Mj60OUBvVQ>? MkXhV2FPT0WU
SK-LMS-1 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rjemlEPTB;Mj60PUBvVQ>? MlzRV2FPT0WU
TGBC1TKB NVOxOJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TRcGlEPTB;Mj62PUBvVQ>? MmPiV2FPT0WU
TE-6 NILxWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnleGpmUUN3ME2yMlc4KG6P NVjWbpc3W0GQR1XS
ETK-1 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7DTWM2OD1{LkiyJI5O MonsV2FPT0WU
BE-13 NXz3PVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwOUmgcm0> MoO5V2FPT0WU
A3-KAW MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITPOI9KSzVyPUKuPVkhdk1? NXrUempyW0GQR1XS
TE-10 M1Xnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTNwMzDuUS=> NU\HfHk5W0GQR1XS
DOHH-2 NH[2fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4TWM2OD1|LkO1JI5O MV\TRW5ITVJ?
ES6 NIDDc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVviOlkzUUN3ME2zMlQ{KG6P M{PEWXNCVkeHUh?=
OPM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTRwMUWgcm0> NVL3ZocyW0GQR1XS
SH-4 M13DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7HTWM2OD12LkO0JI5O Ml3SV2FPT0WU
NB13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH23VIxKSzVyPUSuN|Yhdk1? MX\TRW5ITVJ?
HUTU-80 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7PTWM2OD12LkSyJI5O M1i2WHNCVkeHUh?=
CCRF-CEM NHr0d|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rwPWlEPTB;ND65OEBvVQ>? M33QV3NCVkeHUh?=
TGBC24TKB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj0NmU1UUN3ME21MlUyKG6P MYPTRW5ITVJ?
697 M1jCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO0b3NKSzVyPU[uNlghdk1? MWHTRW5ITVJ?
J-RT3-T3-5 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W5OWlEPTB;Nj60OkBvVQ>? NYDrVm5kW0GQR1XS
KALS-1 NWfEUY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[0c4JKSzVyPU[uOVYhdk1? MUnTRW5ITVJ?
no-10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTdwMkmgcm0> M2Wz[nNCVkeHUh?=
SK-NEP-1 NGqwZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rtSGlEPTB;OD63PUBvVQ>? NEnzO3FUSU6JRWK=
L-540 NUTwbYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD0[IdKSzVyPUGwMlQzKG6P NUezSFFvW0GQR1XS
JiyoyeP-2003 NHO2VHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7JPI5KSzVyPUGwMlk1KG6P NGL3TGxUSU6JRWK=
HH MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jmZmlEPTB;MUGuN|khdk1? M3GyW3NCVkeHUh?=
SR NHvxPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7IUohoUUN3ME2xNU41PSCwTR?= MV7TRW5ITVJ?
QIMR-WIL NGLudGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFzLki1JI5O NIjRNmZUSU6JRWK=
A4-Fuk MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF|LkGyJI5O NYXpUWl2W0GQR1XS
CESS M2\zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULwcVh{UUN3ME2xN{4yOyCwTR?= MX;TRW5ITVJ?
KE-37 NULWOpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rIOmlEPTB;MU[uNFchdk1? MorqV2FPT0WU
SK-UT-1 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF4LkixJI5O Mkj5V2FPT0WU
SIG-M5 NVrMV|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\DW2JKSzVyPUG3MlI2KG6P NWDJOo57W0GQR1XS
HT Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS5Z21jUUN3ME2xO{43KG6P MnviV2FPT0WU
DEL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD3U4lKSzVyPUG3Mlk6KG6P M{DaXHNCVkeHUh?=
SK-PN-DW M4nFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;KbGlEPTB;MkCuNlMhdk1? NYDnSlh6W0GQR1XS
RPMI-8402 NGXvblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M172emlEPTB;MkGuO|chdk1? MljXV2FPT0WU
RPMI-6666 M1;0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H4SmlEPTB;MkSuOFIhdk1? M{nkcHNCVkeHUh?=
NCI-H720 M{HaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF71XVJKSzVyPUK1MlQyKG6P NULEOFVUW0GQR1XS
EW-16 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ4Lki3JI5O NFrYOppUSU6JRWK=
BL-70 NEP3boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ6LkO4JI5O M1TBVXNCVkeHUh?=
SF126 M4XnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWToSZV7UUN3ME2zNE4{QCCwTR?= Ml7hV2FPT0WU
BC-1 M3fkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrhO|BKSzVyPUOxMlI3KG6P NW\BWJZlW0GQR1XS
MHH-PREB-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn4RWxKSzVyPUOyMlQ1KG6P NGL2R21USU6JRWK=
A101D NE[zR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\vdmlEPTB;M{KuOlIhdk1? M2T3XHNCVkeHUh?=
NMC-G1 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnZTWM2OD1|Mz62O{BvVQ>? MYPTRW5ITVJ?
LB1047-RCC MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\obmxKSzVyPUO0MlY6KG6P NX64TVJiW0GQR1XS
EM-2 NHH5dZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN6LkWzJI5O MV7TRW5ITVJ?
COLO-684 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\BTGlEPTB;M{muPEBvVQ>? Ml6yV2FPT0WU
Becker NYnvWW5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRzLkC1JI5O M{LNfnNCVkeHUh?=
BL-41 M1e2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HhZ2lEPTB;NEOuOlYhdk1? M2CyRXNCVkeHUh?=
MDA-MB-134-VI MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LERWlEPTB;NESuNFIhdk1? NIjXUJBUSU6JRWK=
L-363 NYf5UWw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR2LkezJI5O MXPTRW5ITVJ?
ECC4 NETwc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnyPJhKSzVyPUS0Mlc5KG6P M1PiV3NCVkeHUh?=
A388 NYDzO2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fwemlEPTB;NESuPFIhdk1? MWnTRW5ITVJ?
HEL NYfyZnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjudHFKSzVyPUS5Mlc6KG6P M4nN[nNCVkeHUh?=
RKO Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVyLkK5JI5O NFvPOWJUSU6JRWK=
KINGS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13H[GlEPTB;NUGuOVUhdk1? NHq2Z45USU6JRWK=
EB-3 NUH6TVVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXruV4JqUUN3ME21Nk43PyCwTR?= M1jqNXNCVkeHUh?=
ARH-77 NIDpN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rkZWlEPTB;NUKuPEBvVQ>? MVLTRW5ITVJ?
GCIY MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnORWVpUUN3ME21N{41PiCwTR?= M3njXHNCVkeHUh?=
NCI-H1304 NGq1XY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P6W2lEPTB;NUeuNlIhdk1? MnrSV2FPT0WU
KARPAS-299 M{L6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPxOoh3UUN3ME22NU45OiCwTR?= NELpTXpUSU6JRWK=
IA-LM NHG4cHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjjSoJPUUN3ME22PE4yOyCwTR?= NFq5[HlUSU6JRWK=
GI-1 M3TvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vrOmlEPTB;N{CuN|khdk1? NYrKUlJwW0GQR1XS
TE-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;3TWM2OD15Nz6xO{BvVQ>? MVHTRW5ITVJ?
LS-411N NVHrNpd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\qUY5NUUN3ME23O{42PyCwTR?= M1j6SHNCVkeHUh?=
no-11 M2jiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTh|LkK0JI5O MX;TRW5ITVJ?
MV-4-11 NGjycHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTh|LkezJI5O NYOwUogzW0GQR1XS
BV-173 NES1TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z3ZWlEPTB;OEOuPVchdk1? MVLTRW5ITVJ?
CMK NGO1cItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljpTWM2OD16ND6xOkBvVQ>? NXS5Uo5mW0GQR1XS
LC4-1 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorYTWM2OD16Nj63NkBvVQ>? NU\XPZJ2W0GQR1XS
COR-L279 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r4W2lEPTB;OEeuNlUhdk1? M3vCXHNCVkeHUh?=
NCI-H209 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Tu[GlEPTB;OEeuOFEhdk1? NXfXXIN4W0GQR1XS
Raji MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O1e2lEPTB;OEmuO|Ihdk1? MVvTRW5ITVJ?
LB996-RCC M{PYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTl|LkSzJI5O MlL2V2FPT0WU
NCI-H526 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojMTWM2OD17Mz61PUBvVQ>? NHKwdo5USU6JRWK=
KGN NVvxWVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLyTWM2OD17Nj6yPUBvVQ>? MmLtV2FPT0WU
MOLT-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn60TWM2OD17Nj63PUBvVQ>? MYfTRW5ITVJ?
PF-382 NI\ybmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Tkd2lEPTB;OU[uO|khdk1? MXnTRW5ITVJ?
BC-3 M{PQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTl7LkG4JI5O MnzNV2FPT0WU
KARPAS-422 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFyMj6wPUBvVQ>? MYLTRW5ITVJ?
SBC-1 M2HWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nHXWlEPTB;MUC3Mlc2KG6P MmLvV2FPT0WU
LC-1F MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DRfGlEPTB;MUC4MlA2KG6P MkLuV2FPT0WU
GB-1 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO1R5JKSzVyPUGwPU4xOiCwTR?= M1H1OXNCVkeHUh?=
SNB75 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzOT62PUBvVQ>? MonJV2FPT0WU
BB65-RCC NVP5WXJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn73TWM2OD1zMUmuPVMhdk1? MYLTRW5ITVJ?
NCI-N87 M33O[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PXcWlEPTB;MUKxMlk5KG6P NGTZT41USU6JRWK=
IST-MEL1 M{PQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XmemlEPTB;MUKyMlM5KG6P MUPTRW5ITVJ?
HOP-62 NVGxU4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF{Nj64PUBvVQ>? MoTrV2FPT0WU
ACN M4TvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF2Nj63OUBvVQ>? M1X4OnNCVkeHUh?=
DMS-114 M2L5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF3MD62O{BvVQ>? MUXTRW5ITVJ?
MLMA M3fke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrSR4ZKSzVyPUG1PU45QCCwTR?= MnHrV2FPT0WU
HT-144 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XSOmlEPTB;MU[1MlQ{KG6P NInZO2NUSU6JRWK=
C2BBe1 M1nIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnaUVBxUUN3ME2xOlcvPzZibl2= MULTRW5ITVJ?
L-428 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF5Nz63JI5O NIqzfYVUSU6JRWK=
DU-4475 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P1ZmlEPTB;MUi3MlY5KG6P NGT5VGxUSU6JRWK=
CP67-MEL M{LWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF7OT6zPEBvVQ>? MUDTRW5ITVJ?
MEG-01 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LsVGlEPTB;MkCxMlk3KG6P M3HJ[XNCVkeHUh?=
IST-SL2 M1y2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGwTWM2OD1{MEiuOlMhdk1? MWHTRW5ITVJ?
ES8 M4SyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;OWWlEPTB;MkK1Mlk1KG6P MlfnV2FPT0WU
COLO-800 M2OzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjPWmpKSzVyPUKzOU4zQCCwTR?= MULTRW5ITVJ?
MFH-ino M2W2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u3[2lEPTB;MkO1Mlg1KG6P MWjTRW5ITVJ?
OVCAR-4 NV65NZNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ|Nz6yOEBvVQ>? MnHhV2FPT0WU
PSN1 NYrrVI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf3bXRNUUN3ME2yOFIvPzFibl2= MlfVV2FPT0WU
EW-12 M4DmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP0TJE{UUN3ME2yOFMvOSCwTR?= NVi2fHNYW0GQR1XS
HCC1599 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS5[oNPUUN3ME2yOlEvPDdibl2= MV\TRW5ITVJ?
SJSA-1 NX\BTYY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS2eHljUUN3ME2yO|EvPDZibl2= NEPuTnRUSU6JRWK=
ST486 NUHGbHRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe2XYFKSzVyPUK5Ok4yPCCwTR?= Mo\sV2FPT0WU
NOMO-1 NFfqWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNyMD6yNUBvVQ>? M1XCXXNCVkeHUh?=
MN-60 M1TFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzTNW9KSzVyPUOwOU4{OiCwTR?= MV;TRW5ITVJ?
HCC1187 NGm3W5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNyNz6yOUBvVQ>? M4DGS3NCVkeHUh?=
SW982 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;FTWM2OD1|MUSuO|Uhdk1? NInLVVVUSU6JRWK=
LB647-SCLC M3LlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN{OD63NUBvVQ>? NGDaeXhUSU6JRWK=
HC-1 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfjTWM2OD1|M{WuOUBvVQ>? MXvTRW5ITVJ?
EHEB M{HOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTN|Nz61NkBvVQ>? NWG2UYJXW0GQR1XS
TUR MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXRSHRbUUN3ME2zOlMvQTVibl2= NWPSPJdPW0GQR1XS
LU-139 M2T0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H6[mlEPTB;M{e4MlAzKG6P MVLTRW5ITVJ?
NB1 NWj0epBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPKNZFKSzVyPUO4OE41PSCwTR?= M4f6dXNCVkeHUh?=
BB30-HNC NXjVeY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrYTWM2OD1|OEiuN|Ihdk1? NFHidXBUSU6JRWK=
HAL-01 M2na[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6zTWM2OD1|OEmuNlYhdk1? NFu0bnVUSU6JRWK=
K5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfMTWM2OD12MUGuN|chdk1? M4XRNXNCVkeHUh?=
MZ2-MEL M2TjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PmXWlEPTB;NEGzMlY1KG6P MkDSV2FPT0WU
RXF393 MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu5fZdKSzVyPUSxOk41PSCwTR?= NFXZdGFUSU6JRWK=
NCI-H1648 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfJUItKSzVyPUSxO{42OyCwTR?= MXXTRW5ITVJ?
TE-12 NU\q[GN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULING17UUN3ME20N|QvOjZibl2= NHXFVYlUSU6JRWK=
EoL-1- NYPJRZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR|Nz65PEBvVQ>? MYnTRW5ITVJ?
JAR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR|OD62NkBvVQ>? MknGV2FPT0WU
DSH1 Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzhTWM2OD12NUiuPVEhdk1? M160e3NCVkeHUh?=
NCI-H187 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPLTWM2OD12NkKuPFEhdk1? NWXlNYFFW0GQR1XS
HCE-4 NUfRO49PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTR5Nz62OkBvVQ>? MYDTRW5ITVJ?
8-MG-BA NGLyfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTV6MT61NkBvVQ>? M4DSZ3NCVkeHUh?=
KLE MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTV6NT6yJI5O MYLTRW5ITVJ?
KNS-42 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfzXJU5UUN3ME21PFYvQDFibl2= NYf1bYtrW0GQR1XS
MSTO-211H M2\GZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHKWlBKSzVyPU[wPU44PCCwTR?= Mkn5V2FPT0WU
GDM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvQNFE5UUN3ME22NVQvODlibl2= NEPoblNUSU6JRWK=
TE-1 M1H5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnxeHpKSzVyPU[0Ok4yOiCwTR?= MVnTRW5ITVJ?
BT-474 NWjqd4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPrOWxKSzVyPU[0O{4xPiCwTR?= MYnTRW5ITVJ?
KARPAS-45 NUPDVpN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXHbVVKSzVyPU[0O{43KG6P MV\TRW5ITVJ?
MOLT-16 NHXNbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\zPFhKSzVyPU[0O{46OyCwTR?= NIfjPWRUSU6JRWK=
KURAMOCHI NHzKPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX4TWM2OD14NUeuOVEhdk1? NVeyUHk1W0GQR1XS
K-562 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHmZY1FUUN3ME22OlkvPTFibl2= NGLPeIdUSU6JRWK=
EKVX MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DJUWlEPTB;NkeyMlcyKG6P MlXtV2FPT0WU
GAK MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHzRW44UUN3ME22O|UvOyCwTR?= NFHYPFlUSU6JRWK=
NCI-SNU-5 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTZ7MD6wNUBvVQ>? NW\0WJFnW0GQR1XS
NCI-H2126 NXPLWlljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTd{Nj64O{BvVQ>? MXnTRW5ITVJ?
CTV-1 M13pO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnENnpKSzVyPUe0OE46KG6P NXXocph6W0GQR1XS
SW962 M1XRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PSbGlEPTB;N{S4MlQ1KG6P NVHFWVZLW0GQR1XS
MONO-MAC-6 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTd3Nj65N{BvVQ>? MmLrV2FPT0WU
NCI-H748 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;iSZVTUUN3ME23OVgvQTlibl2= NH61dYhUSU6JRWK=
NCI-H524 NV3oWHBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLyTWM2OD15OECuO|Mhdk1? MlLxV2FPT0WU
LS-123 M4fFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO0[W1KSzVyPUe5OU43QSCwTR?= NIXYOWdUSU6JRWK=
NB7 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRThzND6xOEBvVQ>? MlPkV2FPT0WU
LS-1034 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT6WGR5UUN3ME24NlgvQThibl2= MYDTRW5ITVJ?
TE-5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVznfXdOUUN3ME24PFMvPTZibl2= NV;FeI1yW0GQR1XS
A704 NYjZ[JNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDvTWM2OD16OUmuNVUhdk1? NUK2NnBDW0GQR1XS
TK10 NXvaZ3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLmXlAxUUN3ME25NVYvODNibl2= MkDwV2FPT0WU
NCI-H345 NXvlWmo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLWTWM2OD17NEOuNlIhdk1? Ml3sV2FPT0WU
CGTH-W-1 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTl2OD6xN{BvVQ>? M4r6SXNCVkeHUh?=
NCI-H510A MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XVPGlEPTB;OUi1MlEzKG6P M1rNbXNCVkeHUh?=
NCI-H1963 NFrUdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrubHNjUUN3ME2xMlA{Ojl{IN88US=> NHLrN5NUSU6JRWK=
SCC-3 NX3vcJFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWxcpliUUN3ME2xMlA{PDF2IN88US=> M3vnfnNCVkeHUh?=
EW-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37w[mlEPTB;MT6wPFc1OyEQvF2= MnXIV2FPT0WU
CPC-N MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZd2lEPTB;MT6wPFgh|ryP NVPlbGZTW0GQR1XS
NCI-H1417 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjacYtKSzVyPUGuNVIzPiEQvF2= MUfTRW5ITVJ?
DG-75 NXPSfWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPqeJNKSzVyPUGuNVYzQDVizszN M3nDSnNCVkeHUh?=
HD-MY-Z NGXze2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4S45nUUN3ME2xMlE3PDF4IN88US=> NY\Ec2VFW0GQR1XS
ATN-1 NHGzR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYTWM2OD1zLkK2NlA6KM7:TR?= NXTYXWJ1W0GQR1XS
KM-H2 M2OwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX1TlBUUUN3ME2xMlI3PDB6IN88US=> NULNVHdPW0GQR1XS
NCI-H2081 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPNPWlWUUN3ME2xMlI3PjN5IN88US=> NV;Kc5lqW0GQR1XS
HL-60 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\D[2lEPTB;MT6yOlk2QSEQvF2= NVXMOYZEW0GQR1XS
DB NHjOTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHYfo1NUUN3ME2xMlI4OjR{IN88US=> MlvuV2FPT0WU
NCI-H1522 NGTiXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwMki4PFch|ryP M3WwN3NCVkeHUh?=
AM-38 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjKdoNKSzVyPUGuN|A4OiEQvF2= MofQV2FPT0WU
NCI-H446 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm1TWM2OD1zLkOyNVIyKM7:TR?= MYTTRW5ITVJ?
SU-DHL-1 NEKydHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj6U3gxUUN3ME2xMlMzQDBzIN88US=> MWfTRW5ITVJ?
NH-12 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2frVWlEPTB;MT6zOlM4PCEQvF2= M1\TTXNCVkeHUh?=
DMS-79 M{TpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHTTWM2OD1zLkO2PFY3KM7:TR?= NHnGfmdUSU6JRWK=
NCI-H716 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLxb2RrUUN3ME2xMlM5QTh4IN88US=> NXLuPVFWW0GQR1XS
ML-2 NVvvdJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u1dGlEPTB;MT60NVUzQSEQvF2= NYLzPXB4W0GQR1XS
NB10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmeyTWM2OD1zLkS2OlMzKM7:TR?= MU\TRW5ITVJ?
ONS-76 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XETWlEPTB;MT61N|U3QSEQvF2= Ml7lV2FPT0WU
LOUCY NFfkOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXEdYh{UUN3ME2xMlU1PjV5IN88US=> MnTtV2FPT0WU
SCLC-21H NUTsZpNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTLNHlKSzVyPUGuOVg2QDJizszN M2ixZ3NCVkeHUh?=
TGW MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwNkO5O|Uh|ryP NV;ZXYQ1W0GQR1XS
LXF-289 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfLNppVUUN3ME2xMlc{OjZ6IN88US=> NYX3W4h3W0GQR1XS
BB49-HNC M1KwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELPfHFKSzVyPUGuO|M2QDZizszN MX7TRW5ITVJ?
NCI-H747 NVi4WllzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrzT5JlUUN3ME2xMlc2OzR4IN88US=> M3fEVXNCVkeHUh?=
LU-165 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLnUndKSzVyPUGuPFQ6QDZizszN NInsR4dUSU6JRWK=
OMC-1 NGrtOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSxRpo4UUN3ME2xMlk2ODZ4IN88US=> NHvtWIpUSU6JRWK=
RCC10RGB MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwOUW4NVch|ryP MXzTRW5ITVJ?
SW684 NFHPc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLITWM2OD1zLkm2NFk6KM7:TR?= M4fRVXNCVkeHUh?=
TE-8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HydGlEPTB;Mj6wOVU2QSEQvF2= NITqcWxUSU6JRWK=
SK-N-DZ M{T5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnodopKSzVyPUKuNVMzPzRizszN NVu0b4NTW0GQR1XS
EVSA-T MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK3PGRKSzVyPUKuNVc{OTVizszN MWXTRW5ITVJ?
KASUMI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MniyTWM2OD1{LkG4PFE2KM7:TR?= M4ntbnNCVkeHUh?=
NKM-1 NUTpdFdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfMZYZKSzVyPUKuNlU1PzJizszN NVvYZ2xZW0GQR1XS
CAL-148 NX;tZmZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmflTWM2OD1{LkOzOlE1KM7:TR?= M4DGWHNCVkeHUh?=
NCI-H64 NFLL[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKzUYFUUUN3ME2yMlM1OjN{IN88US=> MWHTRW5ITVJ?
KNS-81-FD NHHaPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJwM{[2NkDPxE1? NVjtR4tVW0GQR1XS
KM12 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnZWVBKSzVyPUKuOFA5OzlizszN M2DJUXNCVkeHUh?=
SW954 M3ThRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwNEe3O|kh|ryP MUHTRW5ITVJ?
NCI-H1395 NULBOGlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTyN4dKSzVyPUKuOVI3PDVizszN NF;FVZNUSU6JRWK=
DJM-1 M3yydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTqclBHUUN3ME2yMlYxPjNizszN MlLmV2FPT0WU
COLO-668 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj6UZhqUUN3ME2yMlgzPjl3IN88US=> NUjo[3B7W0GQR1XS
NCI-H1436 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n4VmlEPTB;Mj64OVYyPSEQvF2= MUPTRW5ITVJ?
LB2241-RCC NH\aW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPvTWM2OD1{Lki2PFM6KM7:TR?= NFT2S|hUSU6JRWK=
GT3TKB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TTRWlEPTB;Mj64PVA2PSEQvF2= Mmi1V2FPT0WU
COLO-824 NIHNN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJwOEm3Olgh|ryP M{TrW3NCVkeHUh?=
ES1 NHzN[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoftTWM2OD1{Lki5PFc6KM7:TR?= NHrUSGpUSU6JRWK=
LB771-HNC M4DPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvHPFlKSzVyPUKuPVA6PDZizszN NUTWPHd[W0GQR1XS
GI-ME-N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfQXVJvUUN3ME2zMlAxQTB2IN88US=> NUX3UFBbW0GQR1XS
NALM-6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnUcnVrUUN3ME2zMlAxQTN|IN88US=> M2PwZnNCVkeHUh?=
LU-134-A NYTQcoJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwMEW0NlUh|ryP NH\wVIlUSU6JRWK=
DMS-153 NX\xenZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r1T2lEPTB;Mz6wOVgzPCEQvF2= NYLrO2NOW0GQR1XS
MZ1-PC MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDXNFZSUUN3ME2zMlA6ODd6IN88US=> NVj6[JczW0GQR1XS
NCI-H1155 NVfhNlVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP4TWM2OD1|LkGxOlEh|ryP M160O3NCVkeHUh?=
CAS-1 NGHucGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV70[GxjUUN3ME2zMlE{PzB5IN88US=> NUDEU3BIW0GQR1XS
D-502MG MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXmNGVKSzVyPUOuNVQ{QSEQvF2= NWHNfZdEW0GQR1XS
NCI-H2141 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfZN5kzUUN3ME2zMlE4PDV{IN88US=> MX3TRW5ITVJ?
NB6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTqTWM2OD1|LkG4NlU6KM7:TR?= NUHXNVMzW0GQR1XS
NCCIT MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrGTnh[UUN3ME2zMlIyQDB7IN88US=> MoTRV2FPT0WU
NB69 M1jQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC1TWM2OD1|LkOxPFkyKM7:TR?= MXPTRW5ITVJ?
JVM-2 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XjZmlEPTB;Mz6zOlQ{OyEQvF2= NEDzco5USU6JRWK=
K052 M{XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHFTZU2UUN3ME2zMlM4QTZ6IN88US=> NUjafpVkW0GQR1XS
HCC2157 NGrSS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HCU2lEPTB;Mz61N|IzQCEQvF2= MnTYV2FPT0WU
KMOE-2 NIT3U4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDXRZpwUUN3ME2zMlU1OjR{IN88US=> NUPkUGJSW0GQR1XS
SF268 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7TTWM2OD1|LkexOVU1KM7:TR?= NFnEZ5ZUSU6JRWK=
CHP-126 M4nLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDJUVJKSzVyPUOuO|Y1PThizszN NFu3O4VUSU6JRWK=
CP66-MEL M1KyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XHSGlEPTB;Mz63PVA6PCEQvF2= MmXXV2FPT0WU
NCI-H69 NIHuVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m3N2lEPTB;ND6wNVk{PiEQvF2= MWnTRW5ITVJ?
A253 NWrNWWlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPLTGVEUUN3ME20MlAzOTBzIN88US=> M3nGUnNCVkeHUh?=
NB14 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfyTWM2OD12LkGwOFc6KM7:TR?= NH7BenNUSU6JRWK=
NCI-H1694 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwMUOxNVIh|ryP Mk[3V2FPT0WU
NCI-H2196 NVXUXHRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq3PFA4UUN3ME20MlE4OTZ7IN88US=> NH74XHpUSU6JRWK=
TE-9 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LlcmlEPTB;ND6xO|U5OiEQvF2= M3LuNHNCVkeHUh?=
D-283MED M16wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfQTWM2OD12LkG4PFQh|ryP M1vHTnNCVkeHUh?=
OCI-AML2 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrKOXNlUUN3ME20MlE6PDh7IN88US=> NXuyOJh7W0GQR1XS
D-263MG M3m0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:zT2x3UUN3ME20MlIzQTZzIN88US=> Mnu0V2FPT0WU
MPP-89 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFewW3RKSzVyPUSuNlc{ODRizszN MkXsV2FPT0WU
LAMA-84 NHfZUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrkcW04UUN3ME20MlMxPDJzIN88US=> MnjLV2FPT0WU
LB373-MEL-D MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XaRWlEPTB;ND6zOlc5QSEQvF2= M4f6e3NCVkeHUh?=
UACC-257 NFnCdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPZeo5KSzVyPUSuN|k2OzRizszN MU\TRW5ITVJ?
MC-CAR NXnvc2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwNEO5PUDPxE1? NX3nUWJuW0GQR1XS
COLO-320-HSR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjTWM2OD12LkS0OFI4KM7:TR?= MnPNV2FPT0WU
P30-OHK NEO5WJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XnZWlEPTB;ND62OlU5OSEQvF2= NH\ae45USU6JRWK=
UACC-812 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;WRmlEPTB;ND62PVE3OSEQvF2= MmDMV2FPT0WU
CTB-1 NFX3ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvUcWpKSzVyPUSuO|E2PTVizszN NYPyUGt{W0GQR1XS
ALL-PO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPa[|FKSzVyPUSuPFQxPzdizszN M4nCT3NCVkeHUh?=
SK-MEL-2 M1TqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP5VY1LUUN3ME20Mlg3QTV3IN88US=> MXPTRW5ITVJ?
TC-YIK MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3kTWM2OD12Lkm3PVQzKM7:TR?= MVzTRW5ITVJ?
NCI-H1882 M1;2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLlTWM2OD13LkCyNFAyKM7:TR?= NEnpZWNUSU6JRWK=
MHH-CALL-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfyeYdKSzVyPUWuNFUxPDJizszN NUT6bHJpW0GQR1XS
U-87-MG MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf6SXlxUUN3ME21MlA6PDZ4IN88US=> MXzTRW5ITVJ?
NCI-H1092 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTzTWM2OD13LkK2OVU2KM7:TR?= NX7GcWR2W0GQR1XS
TE-441-T NGO2SopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[3TWM2OD13LkK3PFIh|ryP MX3TRW5ITVJ?
SK-MEL-1 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELKZXFKSzVyPUWuNlkxPDRizszN MkHjV2FPT0WU
EW-22 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPCTWM2OD13LkK5OFY3KM7:TR?= M164S3NCVkeHUh?=
MZ7-mel M1nPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rWdWlEPTB;NT60NFY6OSEQvF2= MXrTRW5ITVJ?
LP-1 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjxdY9RUUN3ME21MlQyOjlzIN88US=> MoTtV2FPT0WU
NCI-SNU-16 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzjeZZKSzVyPUWuOlQxPzRizszN M3\UenNCVkeHUh?=
LU-65 NX33UpV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTVwN{[zO|Mh|ryP MnzGV2FPT0WU
CW-2 NEDIWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHoe|lKSzVyPUWuPFU6PTlizszN NISxc3FUSU6JRWK=
WSU-NHL NFTTVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzFd4tKSzVyPUWuPVUyPzRizszN NHy2RYtUSU6JRWK=
IST-MES1 NU\L[pFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PST2lEPTB;NT65OVQ1OyEQvF2= MYPTRW5ITVJ?
U-266 M3m5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\5U25{UUN3ME21Mlk5OjB{IN88US=> MUnTRW5ITVJ?
TALL-1 NGXhSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDUWIpKSzVyPU[uNVQ3QDhizszN NF7wVohUSU6JRWK=
Calu-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTZwMUWzNVYh|ryP NH3xTpdUSU6JRWK=
MMAC-SF NF3neWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwMUi1OVYh|ryP MVvTRW5ITVJ?
NCI-H82 NXXSdHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG0PXhJUUN3ME22MlIxPDh7IN88US=> M4Xx[3NCVkeHUh?=
RS4-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHDTWM2OD14LkK1PFk4KM7:TR?= MX7TRW5ITVJ?
SNU-C2B NV6yeI9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITHW|NKSzVyPU[uOFA6PjlizszN M2TncnNCVkeHUh?=
BOKU M13mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTZwNEe1PVch|ryP MlzEV2FPT0WU
C8166 NIP4TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHTPGpFUUN3ME22MlU2QTF{IN88US=> M2\6NHNCVkeHUh?=
D-247MG NIDWUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nyUmlEPTB;Nz6wOFM1PyEQvF2= MXHTRW5ITVJ?
EW-18 NFXMZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdwMEeyPVIh|ryP M2[3c3NCVkeHUh?=
KG-1 M4nBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvETWM2OD15Lk[yO|M5KM7:TR?= MW\TRW5ITVJ?
REH NYrtZ2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTlTWM2OD15Lk[4NVA6KM7:TR?= MnX0V2FPT0WU
U-698-M MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kTWM2OD15Lki0N|E2KM7:TR?= MkO0V2FPT0WU
KP-N-RT-BM-1 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXB[GlwUUN3ME23Mlk{ODJ7IN88US=> Mk\GV2FPT0WU
MS-1 M4DFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\JSmlEPTB;Nz65OlA1OSEQvF2= M4fzeHNCVkeHUh?=
SNU-C1 NE\DU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrVO2hKSzVyPUeuPVgyQTJizszN M4T0SXNCVkeHUh?=
SK-MM-2 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILGRoVKSzVyPUiuNlYxPjVizszN NH\zVlRUSU6JRWK=
LAN-6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJVW9DUUN3ME24MlMxODBzIN88US=> M4PRcXNCVkeHUh?=
NEC8 M2nEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfSOoRKSzVyPUiuN|A3QTFizszN NVHLTldvW0GQR1XS
NCI-H1770 NWTuUIxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HXTmlEPTB;OD6zPFAxOiEQvF2= NVPYPWxbW0GQR1XS
D-336MG NYT0[nJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DTOmlEPTB;OD60NFEyPiEQvF2= NY\2bHg1W0GQR1XS
COLO-829 NV:x[JFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfUUYFKSzVyPUiuOFg5PzlizszN NYXiSm15W0GQR1XS
LS-513 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2exZmlEPTB;OD61PVU6QSEQvF2= NVyxN5huW0GQR1XS
YT MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRThwNkK0Nlch|ryP MnHPV2FPT0WU
EW-24 NYfseFZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzrb4p3UUN3ME24Mlc3PTRizszN NYjBd2N6W0GQR1XS
IST-SL1 M2OzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXBXG1bUUN3ME24Mlg3PTR|IN88US=> MXHTRW5ITVJ?
CA46 NF;LNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRThwOUWwPVgh|ryP MYTTRW5ITVJ?
NCI-H1838 NYr4VIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjHfW1[UUN3ME24Mlk5PjB{IN88US=> M2X5fHNCVkeHUh?=
NCI-H719 NYDTRnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS0fpF5UUN3ME25MlI2Ojd7IN88US=> MVXTRW5ITVJ?
HCE-T MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTMXFZbUUN3ME25MlMxQDVzIN88US=> MnT3V2FPT0WU
A498 M4j2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH4TWM2OD17LkO2NVI1KM7:TR?= NH3GZlFUSU6JRWK=
LB831-BLC NGPIZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC5VIVKSzVyPUmuO|Y2OjFizszN MW\TRW5ITVJ?
SKM-1 NFz4bnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrTTWM2OD17Lki1PVY{KM7:TR?= MWfTRW5ITVJ?
THP-1 NH3NOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPiTHRKSzVyPUmuPVY6OThizszN NUnqRW53W0GQR1XS
SHP-77 M1;1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13LdGlEPTB;MUCuOFA4KM7:TR?= MWfTRW5ITVJ?
EW-3 NWTzSYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHnZoNvUUN3ME2xNE43Ojh7IN88US=> M2C1XnNCVkeHUh?=
KY821 M1\uNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPMbpdKSzVyPUGwMlc3OyEQvF2= NYe1UWg2W0GQR1XS
NCI-SNU-1 NYHsOItLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTsdlNQUUN3ME2xNU4xOjF5IN88US=> NY\XV4ZPW0GQR1XS
HCC2218 NUjO[o5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rWRWlEPTB;MUGuN|k5PiEQvF2= NEK1[lhUSU6JRWK=
IM-9 M3LqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX71dmZxUUN3ME2xNU42OTB4IN88US=> MUPTRW5ITVJ?
NCI-H889 NUKyPHVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYclBKSzVyPUGxMlU{OTNizszN MkDJV2FPT0WU
HDLM-2 NYDDNXBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjCdGJKSzVyPUGyMlQyPTlizszN NFnXWWVUSU6JRWK=
LB2518-MEL NXz3[YJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;a[ohnUUN3ME2xNk43QDF3IN88US=> MmryV2FPT0WU
NCI-H23 NET1e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF|LkK0NlUh|ryP NFG0cJNUSU6JRWK=
NB17 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXYWFRKSzVyPUGzMlQ2PzlizszN NHq4SFVUSU6JRWK=
NCI-H322M M{XGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF2LkSwOlgh|ryP MoXPV2FPT0WU
SUP-T1 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS5TWM2OD1zND60NVMh|ryP M{fRRnNCVkeHUh?=
ES3 NUDtTll3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjPTWM2OD1zNT6wO|A{KM7:TR?= M3L1SXNCVkeHUh?=
ES5 NXT4ZWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH75PG5KSzVyPUG1MlA4QDdizszN NWjXW246W0GQR1XS
NCI-H1650 NXfJNYZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m3dmlEPTB;MUWuOFk4QSEQvF2= MlfEV2FPT0WU
NCI-H226 NUHxSVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[0W2JXUUN3ME2xOU45PzZ6IN88US=> NELWS|VUSU6JRWK=
COR-L88 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfoTWM2OD1zNj6zNVQh|ryP M3;aVnNCVkeHUh?=
SCC-15 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLPSo01UUN3ME2xOk4{QDZ7IN88US=> NUjSfXVpW0GQR1XS
GOTO NHLTeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C3b2lEPTB;MU[uOFc6OyEQvF2= MWTTRW5ITVJ?
SIMA Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILBVlZKSzVyPUG2MlQ5ODJizszN NXvlWJE{W0GQR1XS
NCI-H1299 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\FWmlEPTB;MUeuNVU6OSEQvF2= MYDTRW5ITVJ?
NCI-H1581 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvETWM2OD1zNz60NlE6KM7:TR?= NH3x[HVUSU6JRWK=
MHH-NB-11 NYfvNmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGwT5ZlUUN3ME2xO{46Pjh|IN88US=> Mn\uV2FPT0WU
MFM-223 NUfpWGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCxbW16UUN3ME2xPE4xPTN6IN88US=> M3\BSnNCVkeHUh?=
ES7 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nGOWlEPTB;MUiuOVQ{OSEQvF2= MVvTRW5ITVJ?
JVM-3 M1PDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGez[HJKSzVyPUG4MlcyPyEQvF2= NWraTYZwW0GQR1XS
RL NG\XcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfSc3NKSzVyPUKwMlM5QCEQvF2= MX3TRW5ITVJ?
EC-GI-10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJzLkKwOFEh|ryP M325T3NCVkeHUh?=
LNCaP-Clone-FGC M3zDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfRSY0zUUN3ME2yNU43PzZ6IN88US=> NYDSRld2W0GQR1XS
IMR-5 NXn3OlBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L3cGlEPTB;MkGuPFQ6PCEQvF2= M1jFNnNCVkeHUh?=
KP-N-YS M3jRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULHXGJ[UUN3ME2yNU45PzVizszN NHLFe4lUSU6JRWK=
Mo-T NGTBTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTkS4RCUUN3ME2yNk4zOTh3IN88US=> NVP5T3ZiW0GQR1XS
NCI-H128 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\4TWM2OD1{Mz61PFU{KM7:TR?= MUfTRW5ITVJ?
RH-1 NFnxOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPRTWM2OD1{Mz63PFY3KM7:TR?= Mnq1V2FPT0WU
NCI-H2171 NWiyVoZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LlN2lEPTB;MkSuNlQ5PSEQvF2= MX3TRW5ITVJ?
RPMI-8866 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ4Lke0NkDPxE1? NXLJNYxbW0GQR1XS
SK-N-FI NXvoXoFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTRTWM2OD1{Nz6zPFEyKM7:TR?= NEHMXI5USU6JRWK=
LOXIMVI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ5LkiwOVEh|ryP NHv0W25USU6JRWK=
P31-FUJ NXu3RoxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNzLkWzO|Qh|ryP M3\XOXNCVkeHUh?=
KMS-12-PE NFHRb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ywRWlEPTB;NEmuOVMxOiEQvF2= MWrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

- Collapse

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

- Collapse
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804
Smiles COC1CC(CCC1O)CC(C)C2CC(=O)C(C)\C=C(/C)C(O)C(OC)C(=O)C(C)CC(C)/C=C/C=C/C=C(C)/C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N4CCCCC4C(=O)O2)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04172922 Not yet recruiting Drug: Topical Sirolimus Vascular Anomaly Nemours Children''s Clinic December 1 2019 Phase 1
NCT04128722 Active not recruiting Drug: Sirolimus Oral Liquid Product 1mg/mL Lingual Microcystic Lymphatic Malformations University Hospital Tours November 30 2019 Phase 2
NCT03433183 Active not recruiting Drug: Selumetinib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca October 2 2019 Phase 2
NCT04348292 Recruiting Drug: Durvalumab|Drug: Sirolimus Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8 Emory University|National Cancer Institute (NCI) October 22 2019 Phase 1
NCT03933904 Active not recruiting Drug: Sirolimus Castleman Disease|Castleman''s Disease Multicentric University of Pennsylvania September 25 2019 Phase 2
NCT03972592 Recruiting Drug: Topical 0.1% Sirolimus|Drug: Topical Vehicle Vascular Malformations|Lymphatic Malformation University Hospital Tours|University Hospital Angers June 5 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID